MRM Stock News & Sentiment

Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6% Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6%

Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5% Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5%

TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. “We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM's current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji.

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000 before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount.

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs Inc. (“Mother Labs”), a subsidiary of MEDIROM, and Yasuhiro Hayami, Chief Business Officer of Mother Labs, invested in Mother Labs' Series A financing at a pre-money valuation of of JPY9 billion (as of December 1, 2024, approximately USD $59,000,000). Messrs. Homan and Hayami are committed senior executives of Mother Labs and share MEDIROM's corporate philosophy and vision as well as commitment to future growth potential.

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the pricing of a public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount. The Offering is expected to close on December 11, 2024, subject to the satisfaction of customary closing conditions.

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc.

TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09

TOKYO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”) is pleased to announce that it is capitalizing on its extensive experience operating wellness clinics and healthcare technology to expand into the rehabilitation industry. In doing so, MEDIROM established a wholly-owned subsidiary, MEDIROM Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y's, Inc. Prior to the acquisition by MEDIROM Rehab Solutions Inc., Y's, Inc. owned and operated ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan.